Samsung Biologics has announced its intention to purchase PolyPeptide for $2 billion, marking the largest acquisition in the company's history. The deal, reported on July 19, 2026, represents a record transaction for the South Korean biopharmaceutical contract manufacturer.
Samsung Biologics has disclosed plans to acquire PolyPeptide in a deal valued at $2 billion. The transaction is the largest ever for the South Korean biopharmaceutical contract development and manufacturing organization. The acquisition was announced on July 19, 2026.
The purchase price of $2 billion sets a new record for Samsung Biologics' acquisition history. This deal surpasses the company's previous acquisition expenditures, establishing a significant milestone. The $2 billion figure represents a substantial commitment by Samsung Biologics to expand its capabilities.
PolyPeptide will be acquired by Samsung Biologics as part of this transaction. The deal involves a payment of $2 billion for the target company. The acquisition is intended to strengthen Samsung Biologics' presence in the global biopharmaceutical market. PolyPeptide, a specialist in peptide manufacturing, will become part of the Samsung Biologics portfolio.
This $2 billion acquisition marks a record deal for Samsung Biologics. The transaction underscores the company's strategy to grow through significant acquisitions. The July 19, 2026 announcement confirms Samsung Biologics' ambition to expand its operational footprint. The deal is expected to close following standard procedures, though no specific timeline has been provided in the announcement.
The $2 billion acquisition of PolyPeptide by Samsung Biologics is a notable event in the biopharmaceutical industry. The deal represents the largest acquisition ever undertaken by Samsung Biologics. The transaction demonstrates the company's willingness to invest heavily in expanding its capabilities within the peptide manufacturing space.
Related reading: Samsung Biologics Inks 2.7 Trillion Won Deal and Enters Obesity Peptide Market, Samsung Biologics offers 1.46 billion Swiss francs for PolyPeptide, GLP-1 Bridge program goes into effect; physicians seek accessible treatment options for obesity, Samsung Biologics Plans $1.8 Billion All-Cash Bid for PolyPeptide.